Is the price fair?
What CLOV's price assumes
Today's price asks for 13% free cash flow growth a year; over the last three years Clover Health Investments, Corp. delivered 55%, less than the record.
0.42
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.8%
Free cash flow yield · Healthcare Plans median 6.5%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered +55% a year over the last three.
- Price / book
- 2.76
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 2.76
- EV / EBIToperating margin −0.74%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $74M
- Market capitalisation
- $2.63B
- 3-year free cash flow growth
- +55%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Healthcare Plans
Ranks #2 of 11 by Smart Score